INTRODUCTION
Fibromyalgia syndrome (FMS) is a chronic, generalized and diffuse pain disorder accompanied by symptoms such as morning stiffness or rest, fatigue, depression and sleeping disorders, which etiology is still unknown (Wolfe et al., 1990 (Wolfe et al., , 2010 . The European population has different prevalence rates of FMS, from 1.4% in France to 3.7% in Italy (Branco et al., 2010) . Similar prevalence data have been found in other countries such as North America with an estimated prevalence rate ranging from 2.0% to 3.3% (reviewed in Jones et al., 2015) . However, this rate of prevalence could be increased in relation to the diagnosis criteria used. For example, with the modified 2010 criteria (Wolfe et al., 2011) , the prevalence rate increases to 5.4%, with a ratio of females to males of 2.3:1 (Jones et al., 2015) .
FMS is often associated with other somatic syndromes such as chronic fatigue syndrome (CFS), a condition characterized by 6 months or more of persisting or relapsing fatigue caused by an over-production of pro-inflammatory cytokines; the CFS prevalence rate ranges from 3 to 20% (Penfold, St. Denis, & Mazhar, 2016) . For example, while all patients with CFS present with high levels of fatigue, there is considerable overlap in patients with FMS, with a percentage of 86% reporting fatigue as well (Aaron, Burke, & Buchwald, 2000) . In addition, Aaron and Buchwald (2001) and Buchwald and Garrity (1994) , found that between 35% to 70% of CFS patients met the criteria for FMS, reporting a considerable co-occurrence with CFS (Odds Ratio (OR)=23.2) (Kanaan, Lepine, & Wessely, 2007) .
Although the most common symptom in FMS is pain and in CFS is fatigue, a high prevalence of gastrointestinal symptoms has been reported in both disorders (Aaron et al., 2000) . In fact, 81% of FMS patients reported normal alternating with 6 irregular bowel pattern, and 63% had alternating diarrhoea and constipation (Triadafilopoulos, Simms, & Goldenberg, 1991) . Similarly, 32.2% of CFS patients used various gastrointestinal drugs in comparison with control subjects (14.3%), indicating an OR of 2.67 (Jones, Nisenbaum, & Reeves, 2003) .
Conversely, between 32% to 80% of patients with FMS met the criteria for irritable bowel syndrome (IBS), a common functional disorder of the gastrointestinal tract (Aaron & Buchwald, 2001; Riedl et al., 2008; Sperber et al., 1999; Whitehead, Palsson, & Jones, 2002) , with considerable comorbidities (OR from 1.8 to 5.3) (Kanaan et al., 2007) . Likewise, between 58 and 92% of patients with CFS met criteria for IBS (Aaron & Buchwald, 2001 ).
Cognitive and affective deficits, such as nervousness, memory loss, forgetfulness and confusion, have been documented in patients with CFS or FMS (Glass, 2008; Joyce, Blumenthal, & Wessely, 1996) . Interestingly, it was demonstrated that the severity of these neurological and cognitive deficits is related to reduced levels of Bifidobacterium spp. and increased levels of Enterococcus spp, which have been detected in FMS as well as in CFS (Butt, Dunstan, McGregor, & Roberts, 2001 ). In addition, CFS patients show alterations in gut microbiota suggesting a probable link between intestinal colonization of gram-positive facultative anaerobic D-lactic acid bacteria and symptom expression, these bacteria have been reported to be associated with cognitive dysfunction and neurological impairment in patients with intestinal bacterial overgrowth (Sheedy et al., 2009 ). Pimentel and colleagues (2003) found an abnormal lactulose breath test in FMS patients (78%), which suggested bacterial overgrowth of the small intestine (SIBO), which represents one form of alteration of the normal gut microbiota characterized by a qualitative and quantitative change of the bacterial colonies that inhabit the small intestine. Under normal conditions, the upper 7 tract of the small intestine is mainly colonized by Gram-positive bacteria whose counts do not exceed 10 3 organisms/mL. However, in the case of SIBO, the count of these colonies either increases to or exceeds 10 5 -10 6 organisms/mL (Slim, Calandre, & RicoVillademoros, 2015) . A later research study by Pimentel and colleagues (2004) demonstrated that 100% of FMS patients were diagnosed with SIBO compared to 84%
of subjects with IBS and 20% of healthy subjects.
Other facts indicating that the gastrointestinal system is affected in FMS patients may include hipersensivity to food components, celiac disease, non-celiac gluten sensitivity, lactose intolerance and FODMAPs (Fermentable oligo-, di-, monosaccharides and polyol) (Slim et al., 2015) . An increase in secretory immunoglobulin A (sIgA) has also been observed in FMS (Michalsen et al., 2005) , which is related to fatigue, major depression and gastrointestinal symptoms (Maes, Kubera, & Leunis, 2008 ).
All of the aforementioned findings demonstrate the relevance of microbiota in FMS and CFS, pointing to the potential use of probiotics in these syndromes, as it has been recently suggested by several authors (Galland, 2014; Lakhan & Kirchgessner, 2010; Slim et al., 2015) . Probiotics are live microorganism that, when administered in adequate amounts, confer a health benefit to the host (FAO/WHO, 2001). Several authors suggest that the effects of probiotics may be genus-specific or depend on the species or strain or the dose used (Umbrello & Esposito, 2016) . IBS is one of the populations with more evidence from probiotic treatments (Didari, Mozaffari, Nikfar, & Abdollahi, 2015; Tiequn, Guanqun, & Shuo, 2015) . In fact, pain and symptom severity scores in IBS patients have been reported to be reduced after the consumption of probiotics. Similarly, probiotics have been demonstrated as also useful in patients with SIBO (Khalighi et al., 2014) . In recent years, the interest of the role of probiotics in 8 mood and emotional modulation has increased. Mood and emotional symptoms are also present in patients with FMS and CFS and may be affected by probiotics (Benton, Williams, & Brown, 2007; Messaoudi, Lalonde, et al., 2011; Messaoudi, Violle, et al., 2011; Steenbergen, Sellaro, van Hemert, Bosch, & Colzato, 2015) . Probiotic effectiveness in improving depression and anxiety is produced through the connection between the gut and the brain or gut-brain axis (Carabotti, Scirocco, Maselli, & Severi, 2015; Cryan & O'Mahony, 2011; De Palma, Collins, Bercik, & Verdu, 2014; Diaz Heijtz et al., 2011; Maes et al., 2008; Sherwin, Rea, Dinan, & Cryan, 2016) .
To summarize, the high comorbidity between FMS and CFS with gastrointestinal pathologies, such as IBS, as well as the high gastrointestinal symptomatology presented by these patients has been documented. In addition, several other symptoms presented in FMS and CFS patients, such as anxiety or depression, have been improved through treatment with probiotics in other populations. Altogether, these findings support our hypothesis that the probiotics could improve FMS and CFS symptoms. A better understanding of the probiotic effects in these pathologies is required to develop integrative approaches for patient care. Therefore, the aim of this study was to systematically review the reported effect of probiotic treatments in patients diagnosed with FMS or CFS.
METHODS
In February 2016, a systematic review of clinical trials and pilot studies was conducted. The process of reviews adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009 ). The
Cochrane Handbook for Systematic Reviews (Higgins & Green, 2011) was also 9 consulted. The search was limited to studies published in the last ten years, from 2006 to 2016. The protocol for this review was not registered.
Research Question
The follow structured, Patient-Intervention-Outcomes question (PIO) (Stone, 2002 ) was used as follows: Are probiotics able to reduce or improve symptoms in FMS or CFS patients?
Data sources/Information sources
The search was conducted in a total of 14 electronic bibliographic databases, due to the novelty and multidisciplinary approach of the topic. The search for clinical trials and pilot studies using probiotics for FMS or CFS was conducted using the following: To identify the potential studies in electronic databases, structured by the PIO research question, the following keywords (MeSH or DeCS) were used: patients key words ("fibromyalgia" OR "fatigue syndrome, chronic"), AND intervention keywords ("probiotics" OR "lactobacillus" OR "bifidobacterium"), AND outcomes keywords ("pain" OR "depression" OR "anxiety" OR "fatigue" OR "muscle rigidity" OR "sleep wake disorders" OR "headache" OR "migraine without aura" OR "paresthesia") in the title, key words or abstract. After a preliminary search, it was decided to exclude outcome keywords in the definite searches because they limited too much of the available research.
Study Eligibility Criteria
The following inclusion criteria were used in this review: (1) 
Study Selection and Methodologic Quality
The two first authors carried out the databases search. Next, the studies were selected by the two same authors who, independently and in duplicate, reviewed all studies. If consensus could not be achieved, the third author was consulted and asked for a recommendation to include it or not. The selected data were discussed at a face-toface meeting of all authors (reviewers); all authors also discussed the extracted data.
Full texts of potentially relevant articles were independently appraised by the same two authors using the Jadad Scale for Reporting Randomized Controlled Trials, a checklist with five simple items that help to evaluate the quality of RCTs in a simple way (Clark et al., 1999) . In addition, this scale contains many of the important elements that have empirically been demonstrated to correlate with bias, and it has known reliability and external validity (Halpern & Douglas, 2005) . The scoring is based on the quality of randomization, double blinding, and losses to follow-up and establishes a score of greater than 3 points as high quality and less than 3 points as low quality (Jadad et al., 1996) .
Data Extraction and Data Synthesis 11
The major categories of the coded variables include the following: (1) reference, (2) number of enrolled patients, (3) probiotics used, (4) outcomes and (5) duration of the intervention.
Initially we planned to report the effectiveness of probiotics by using descriptive statistics. However, the few results and the heterogeneity of outcomes measures used across the studies made the meta-analysis impossible. Thus, we decided to report the effectiveness of probiotic treatments by using narrative summaries.
Complementary Search
Complementary searches were performed about other uses of specific probiotic strains used in FMS or CFS patients (Lactobacillus casei strain Shirota and Bifidobacterium infantis 35624). A brief (synthesis) of these results can be found in Table S1 and Table S2 .
RESULTS
From a total of 537 eligible articles found in our initial search, we finally 
Included studies
A total of 2 primary research papers (Groeger et al., 2013; Rao et al., 2009 ) were included in this review (detailed information is demonstrated in Table 1 ). We did not identify any clinical trials. These 2 articles could be considered pilot studies, although only Rao et al. (2009) identified their study as a pilot study. Both studies were randomized and double-blinded. They included 4 groups (2 intervention and 2 control).
Although the study of Groeger and colleagues (2013) included other pathologies and a healthy subject group, in our review, we focused only on the group with CFS patients.
Neither of the included studies was focused on FMS patients. Eighty-three patients diagnosed with CFS, 8 men and 75 women randomly assigned, participated in both studies (the sample sizes ranged from 35 (Rao et al., 2009 ) to 48 (Groeger et al., 2013) ).
All of the included studies clearly described how the sample size was calculated. The age range of the participants was 18 to 65 years old. The studies were conducted in
Ireland and Canada and were published in English. Table 2 presents the assessment of methodological quality and potential risk of bias in the included studies using the Jadad Scale. The study by Rao et al. (2009) obtained a score of 4 points, while the study by Groeger et al. (2013) obtained 3 points;
thus, both studies were considered as a "HIGH range of quality score". 
Effects of intervention
• Specific intervention
The probiotics used in the included studies were the Lactobacillus casei strain Shirota (LcS) (Rao et al., 2009) and Bifidobacterium infantis 35624 (Groeger et al., 2013) . The duration of the treatment for both studies was 8 weeks. More details about the use of these probiotics in other pathologies can be found in Table S1 and Table S2 , as result of a complementary search.
• Gut composition
In the study of Rao et al.(2009) 
the faecal composition of Bifidobacteria and
Lactobacillus was assessed pre-and post-treatment. Compared to the placebo control group, the probiotic group demonstrated moderate increases in total faecal aerobes and anaerobes and significant increases in total faecal Bifidobacteria and Lactobacillus.
Specifically, in the placebo group only 37.5% of subjects demonstrated an increase in Bifidobacteria, whereas 62.5% of participants demonstrated a decrease. In the probiotic group, 73.7% of the faecal samples increased in Bifidobacteria, and 26.3% decreased after the treatment.
Concerning Lactobacillus, in the placebo group, 43.8% increased their levels, while 56.2% decreased. In the probiotic group, 73.7% increased, 21% decreased, and 5.3% had no change.
Summarizing, the total faecal aerobes in comparison with the baseline decreased in the placebo group, while they increased in the probiotic group. With respect to total anaerobes, in the placebo group, they remained almost unchanged, while in the probiotic group, the total increased after the treatment.
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• Anxiety and depression
According to the research of Rao et al.(2009) , the anxiety of CFS patients was evaluated by the Beck Anxiety Inventory (BAI), and a significant decrease (p=0.011) was found in the anxiety scores in the probiotic group, compared with the placebo group. However, no significant difference (p=0.292) in depression, assessed by the Beck Depression Inventory (BDI), was observed among those taking probiotics.
• Inflammatory processes Groeger and et al. (2013) CFS group, the plasma CRP and TNF-α levels increased slightly, while the plasma IL-6 levels remained unchanged after eight weeks of treatment.
Therefore, the individual's biomarkers (CRP, TNF-α, and IL-6; represented by percentage changes from baseline) demonstrated that 71% of CFS patients in the probiotic group displayed decreased levels at week 8, whereas in the placebo group, only 11% of participants demonstrated a decrease in these levels at the same period.
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• Adverse effects and safety of probiotics Rao et al. (2009) demonstrated that the LcS probiotic powder was well tolerated and that there were no significant adverse events reported in the probiotic group or in the placebo group. Groeger et al.(2013) did not assess whether the Bifidobacterium infantis 35624 was well tolerated; however, no significant adverse events were reported in the probiotic group.
DISCUSSION
This systematic review aimed to critically appraise and synthesize the existing empirical evidence on the effectiveness of probiotic administration for the treatment of FMS or CFS symptoms. To the best of our knowledge, this is the first systematic review of the effects of probiotics on these syndromes.
The available research concerning the potential usefulness of probiotic treatment for FMS or CFS is limited. Nevertheless, it seems, from the results of the two studies reviewed here (Groeger et al., 2013; Rao et al., 2009) , that some probiotic strains might improve the symptoms of anxiety and inflammation in these populations.
However, it is worth noting that all the included studies were conducted in CFS patients and that neither of the studies were carried out in FMS patients. Additionally, neither of these studies were focused on fatigue, the core symptom of CFS.
Interestingly, in a study excluded as an exploratory study, Sullivan, Nord and Evengård short-term memory and capacity to concentrate (p=0.040) was affected from baseline to the end of the follow-up (day 72), but no significant differences in fatigue or in the remaining variables measured (health and physical activity) were observed. Another study carried out in patients with spondyloarthritis (Jenks et al., 2010) , using a combination of probiotics (Streptococcus salivarius K12, Bifidobacterium lactis LAFTI B94, and Lactobacillus acidophilus LAFTI L10) for 12 weeks, patients demonstrated no significant benefit over placebo concerning fatigue. Finally, an improvement trend in fatigue (p<0.10) was observed when colorectal cancer patients who received a 12-week probiotic intervention containing Lactobacillus rhamnosus combined with Lactobacillus acidophilus were compared to a placebo group (Lee et al., 2014) .
Although only CFS patients improved in their anxiety scores after receiving probiotics (Rao et al., 2009) , there is much more evidence from other populations concerning both anxiety and depression. For example, Steenbergen et al. (2015) concluded that the intake of a multispecies probiotic for 4 weeks in healthy subjects could reduce negative thoughts associated with a sad mood, suggesting that the probiotic supplementation was a potential preventive strategy for depression. Another study carried out by Messaoudi, Lalonde, et al. (2011) in the general population demonstrated that Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 taken in combination for 30 days decreased the global scores on the Hospital Anxiety and Depression (HAD) scale. Similar results were also found in a population with low urinary free cortisol levels at baseline (Messaoudi, Violle, et al., 2011) . Finally, Akkasheh and colleagues (2016) Several studies have demonstrated beneficial effects from probiotics in IBS, a syndrome with a great comorbidity with CFS and FMS (Aaron & Buchwald, 2001; Kanaan et al., 2007) . Lorenzo-Zúñiga et al. (2014) (Francavilla et al., 2010) and appeared to moderately increase the treatment success (Gawrońska, Dziechciarz, Horvath, & Szajewska, 2007) . This reduction of pain after probiotic treatment was also observed in patients with rheumatoid arthritis. In fact, Mandel, Eichas and Holmes (2010) found that the probiotic group (Bacillus coagulans GBI-30, 6086) experienced a borderline statistically significant improvement in the patient pain assessment score (p=0.052) and a statistically significant improvement in the pain scale (p=0.046) in comparison with the placebo group. Additionally, and in accordance with the results obtained by Groeger et al. (2013) , the probiotic group demonstrated reduced CRP levels compared with the placebo group. Finally, it is worth noting that Ringel-Kulka et al. (2014) provide a possible mechanism of action by which probiotics (L-NCFM) modulate pain sensation in humans through opioid-mediated pathways.
In recent years, accumulating evidence has suggested that probiotics may have a positive effect on health through the brain-gut axis De Palma et al., 2014; Diaz Heijtz et al., 2011; Sherwin et al., 2016) . Communication in this axis would take place via the following three different pathways: neural (mainly by the vagus nerve and the enteric nervous system), endocrine (cortisol) and immune (cytokines) (Carabotti et al., 2015; Cryan & O'Mahony, 2011; Petschow et al., 2013; Zhou & Foster, 2015) . Several proposed mechanisms of action of probiotics include competition against the pathogenic bacteria that bind to the intestinal epithelial cells, enhancement of the intestinal epithelial barrier function, inhibition of pathogen growth by the secretion of antimicrobial peptides, and enhancement of the production of serum IgA as possible mechanisms (Hardy, Harris, Lyon, Beal, & Foey, 2013; Upadhyay & Moudgal, 2012) . It has also been recently suggested that probiotics may affect the central nervous system via the BGA (i) by enhancing the production and delivery of neuroactive substances, such as gamma-amino butyric acid (GABA), serotonin, dopamine and acetylcholine; (ii) by the vagus nerve (Dinan, Stanton, & Cryan, 2013) and (iii) by decreasing pro-inflammatory cytokines, which are able to cross the blood-brain barrier and elicit mood and behavioural changes (Hardy et al., 2013) . For instance, some probiotics have been demonstrated to induce an elevation in tryptophan levels in plasma (Desbonnet, Garrett, Clarke, Bienenstock, & Dinan, 2008) , which is a precursor of serotonin. Serotonin has been implicated in emotional processes, cognition, motor function and pain, as well as in neuroendocrine functions, such as food intake, circadian rhythms and reproductive activity (Martinowich & Lu, 2008) .
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Despite the hypothesis of the usefulness of probiotics in FMS and CFS, this systematic review has shown that, till today, the number of clinical trials is too limited to conclude that probiotics are useful in these pathologies. This fact is due to the unknown etiology and widespread symptoms suffered by these patients. However, these results could be increased in the coming years with incoming clinical trials, controlled and double blind, such as the one that Roman and colleagues are performing from 2017.
This review is not free of limitations. There are some methodological limitations that we must highlight, the protocol of the review has not been registered. In addition,
we imposed date restriction (from year 2006 to year 2016), however, this aspect might not influence in the results as this topic is very recent. Concerning the databases used,
we included a large number that increased the number of repeated results. Likewise, we used "Lactobacillus" and "Bifidobacterium" as descriptors due to that those are the main probiotic strains, but not other strains such as "Streptococcus" or "Pediococcus"
were included. Nevertheless, these and others probiotic strains are included in the descriptor "probiotic", so that this circumstance may not interfere in the results.
CONCLUSIONS
Through this systematic review, we conclude that several probiotic strains (Lactobacillus casei strain Shirota and Bifidobacterium infantis 35624) demonstrate beneficial effects in CFS patients. However, none of the studies were carried out in FMS patients. These reported benefits include decreased anxiety levels and changes in the microbiota composition, as well as a reduction in several systematic inflammatory biomarkers. A large and exhaustive review of the literature was presented, suggesting the possible mechanism involved in these effects. However, due to the reduced number of studies included in this review, more research is required to clarify the possible 
